The phase II clinical trial was published in year 2010, which demonstrated dramatic response and longer progression free survival to crizotinib treatment in patients with EML4-ALK fusion gene [29–31], similar to EGFR–TKI on NSCLC patients with EGFR mutations [3–7]. Here, EGFR is linked to non-small cell lung carcinoma.